1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
ContraFect Corp.

ContraFect Corp.

CFRXQ
ContraFect Corp.US flagOther OTC
0.00
USD
- -
- -
107.00Market Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-2,771.41
-1,765.9
-3,086.44
-861.46
-680.72
-223.29
-396.35
-123.56
-98.95
-44.12
-124.97
-5.62
Free Cash Flow per Basic Share
-2,344.09
-1,050.87
-1,325.32
-760.97
-701.59
-352.97
-277.59
-265.09
-116.63
-89.46
-88.3
-8.29
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-4,918.1
-4,324.22
-8,243.26
-4,031.98
-3,485.2
-2,325.78
-2,096.3
-2,048.55
-844.39
-566.79
-624.72
-79.11
Tangible Book Value per Share
-4,632.3
-3,955.63
2,280.8
1,051.94
465.43
448.87
58.29
150.13
44.35
107.41
-22.73
-1.34
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
4
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
1
1
1
1
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-19
-24
-30
-25
-29
-16
-38
-13
-28
-20
-65
-24
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
3
-3
25
30
32
44
26
21
41
51
-3
-6
LT Debt
1
10
- -
- -
- -
- -
- -
3
3
3
2
2
Total Equity
-32
-13
26
31
20
31
6
16
13
49
-12
-6
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
11
11
Market Capitalization
2
3
2

Working Capital

FRC

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
Total Current Assets
18
17
7
Cash, Cash Equivalents & STI
14
14
5
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
20
16
12
Payables & Accruals
17
14
10
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-6.6%
49.34%
-124%
Free Cash Flow
12.55%
13.67%
11.94%
Net Income, GAAP
39.16%
78.03%
221.24%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-14.35
-10.98
-10.76
-8.95
-44.12
2022
-41
-36.79
-34.72
-16.14
-124.97
2023
-0.69
-1.94
-0.5
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Roger J. Pomerantz
Full Time Employees
23
Sector
Healthcare
Industry
Biotechnology
Address
28 Wells Avenue Yonkers NY United States of America 10701
IPO Date
Sep 12, 2014
Website
contrafect.com
Similar Companies
Cyxone AB (publ) (CYXO.ST)
hVIVO plc (OPORF)
Propanc Biopharma, Inc. (PPCB)
Helix BioPharma Corp. (HBPCF)
Traws Pharma, Inc. (TRAW)
Prescient Therapeutics Limited (PTX.AX)
Business
ContraFect Corporation ContraFect Corporation, a clinical-stage biotechnology company founded in 2008 and headquartered in Yonkers, New York, discovers and develops direct lytic agents (DLAs), including lysins and amurin peptides, as novel therapeutics for life-threatening, antibiotic-resistant infectious diseases treated primarily in hospital settings. Its lead product candidates comprise exebacase (CF-301), a lysin targeting Staphylococcus aureus bacteremia including methicillin-resistant strains; CF-296, an engineered lysin for invasive Staphylococcal infections such as osteomyelitis, prosthetic joint infections, and biofilm-associated conditions; and CF-370, an anti-pseudomonal lysin for Pseudomonas aeruginosa infections like ventilator-associated pneumonia and bloodstream infections; alongside preclinical amurin peptides addressing Gram-negative ESKAPE pathogens. The company targets critical hospital-acquired infections in the United States, leveraging platforms that rapidly lyse bacterial cell walls without promoting resistance. In December 2023, ContraFect Corporation ceased operations and filed for Chapter 7 bankruptcy liquidation in the U.S. Bankruptcy Court for the District of Delaware, with assets listed at approximately $0.61 million and liabilities at $9.32 million, following Nasdaq delisting earlier that year due to failure to meet listing standards. Prior developments included a 2020 equity investment from Pfizer Inc. Pfizer Inc., up to $6.94 million in non-dilutive CARB-X funding for its amurin program in 2019, and preclinical advancements for Gram-negative lysins, though clinical progress such as Phase 3 enrollment for exebacase was halted amid futility concerns. No active subsidiaries or parent relationships are noted post-bankruptcy.